Table 2.

Estimate of disease progression at Day 364—full analysis set.

	Degarelix (n=142)	Goserelin (n=141)	p-Value
No PSA failure	82.8 (75.2–88.2)	73.4 (64.9–80.1)	0.062
PSA-PFS	82.3 (74.7–87.7)	71.7 (63.2–78.5)	0.038
PFS	81.5 (73.9–87.1)	71.7 (63.2–78.5)	0.058

PFS, progression free survival; PSA, prostate-specific antigen.